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Abstract
The objective of this study was to assess the 
prevalence of anemia and the therapeutic and 
prophylactic response to ferrous sulfate and fo-
lic acid. A double-blind, randomized, controlled 
clinical trial was conducted with 196 children 6 
to 24 months of age enrolled in municipal day-
care centers in Goiânia, Goiás State, Brazil. The 
children were assigned to two treatment groups 
that received a daily dose (5 times a week) of ei-
ther 4.2mg/kg/day of ferrous sulfate + folic acid 
(50µg) or 4.2mg/kg/day of ferrous sulfate + fo-
lic acid placebo. One of the prevention groups 
received 1.4mg/kg/day of ferrous sulfate + folic 
acid (50µg/day) and the other 1.4mg/kg/day of 
ferrous sulfate + folic acid placebo. Supplemen-
tation lasted approximately three months. Base-
line anemia prevalence was 56.1% (95%CI: 48.9-
63.1). After treatment, anemia prevalence in the 
folic acid group (14%) was lower than in the 
placebo group (34.9%) (p = 0.02). After prophy-
laxis in the non-anemic children, the incidence 
of anemia did not differ between the groups, but 
there was an increase in hemoglobin level in the 
folic acid group (p = 0.003). Iron plus folic acid 
was effective for the treatment of anemia and 
improvement of hemoglobin level in non-ane-
mic children. 
Nutritional Epidemiology; Anemia; Ferrous Sul-
fate; Folic Acid; Child Day Care Centers
Introduction
Nutritional anemia can be due to iron, folic acid, 
or vitamin B12 deficiency 1. Iron is the main nu-
trient involved in nutritional anemia, followed by 
folic acid 2. Deoxyribonucleic acid (DNA) synthe-
sis depends on the coenzyme folate for the bio-
synthesis of the nucleotide pyrimidine, which is 
required for cell division 3, and folate is thus one 
of the necessary nutrients for hematopoiesis 4.
Iron deficiency anemia is the most common 
nutritional problem in the world 5, with a nega-
tive impact on mental, motor, cognitive, and im-
mune development 6,7,8. An anemia prevalence 
greater than or equal to 40% is considered a seri-
ous public health problem 4, and in Brazil chil-
dren 6 to 24 months of age constitute one of the 
most vulnerable groups 9,10.
The World Health Organization and the Bra-
zilian Ministry of Health recommend that infants 
receive exclusive breastfeeding until six months 
of life 11. It has been shown that absorption of iron 
from breast milk is reduced by the consumption 
of other foods or beverages, particularly before 
or after breatfeeding 12. With the introduction of 
supplementary feeding, infants require an ad-
ditional source of iron to prevent iron deficiency 
anemia 4. Various studies have used various in-
termittent doses at different weekly frequencies 
for anemia prevention and treatment 13,14,15,16. 
Although the use of iron supplements is recom-
mended for infants in areas with high prevalence 
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of anemia, their efficacy has not been totally elu-
cidated 17.
Some studies have suggested that other 
factors besides iron can limit the hemoglobin 
response and control of anemia, like vitamin A 
and other micronutrients or non-nutritional fac-
tors 13. A study of Mexican children showed that 
iron, vitamin A, vitamin B12, vitamin E, and ribo-
flavin deficiencies were common at baseline. The 
authors observed that many children receiving 
iron supplements remained anemic (30%) after 
six months of treatment and at 12 months (31%), 
despite the eradication of iron deficiency 18. Thus, 
supplementation with one or more nutrients is 
one of the strategies to fight borderline micronu-
trient deficiency, since it can increase the effec-
tiveness of programs to fight anemia. However, 
there is still limited information on interactions 
between micronutrients (when supplemented), 
based on pharmacological studies 19. It is impor-
tant to assess the efficacy and effectiveness of 
iron supplementation compared to the combi-
nation of iron and folic acid in children younger 
than 24 months 20. In addition, the possibility of 
meeting the multiple needs for these micronutri-
ents makes this an interesting strategy 21.
The objectives of this study were to evaluate 
the prevalence of anemia in children from 6 to 24 
months of age and the therapeutic and prophy-
lactic response to ferrous sulfate plus folic acid 
on hemoglobin levels, in municipal daycare cen-
ters in Goiânia, Goiás State, Brazil. 
Methods
Sampling
In 2005, Goiânia had 67 municipal preschools, 
of which 53 included daycare centers with 447 
children from 6 to 24 months of age. These are 
fulltime preschools where children participate 
in educational activities with teachers trained in 
pedagogy or teaching, along with preschool staff. 
The centers are operated by the Goiânia Munici-
pal Department of Education.
Children were selected through probabilis-
tic sampling, i.e., the number of children from 6 
to 24 months of age was checked at the munici-
pal preschools that had daycare centers, and the 
probability of the daycare center being picked 
was proportional to the number of children en-
rolled there. Twenty-five daycare centers were 
selected, with 268 children, using a probabilis-
tic draw and the Excel random numbers table 
(Microsoft Corp., USA). After application of the 
exclusion criteria and one refusal, 219 children 
were finally selected.
• Population: universe of children from 6 to 24 
months of age attending municipal preschools 
with daycare in the year 2005.
• Sample: included 219 children from 6 to 24 
months of age, born at term, non-twins, with pa-
rental approval for participation in the study, and 
who were attending municipal daycare centers 
with more than four children each. Exclusion cri-
teria were: children with special needs, low birth 
weight (< 2,500g), with growth-impairing heart 
diseases or neurological syndromes, with sickle-
cell anemia or sickle-cell trait, under treatment 
for anemia at the time of the first interview or 
screening performed by the pediatrician, and 
those no longer attending the daycare center. The 
clinical trial excluded children with hemoglobin 
≥ 7 and < 8g/dL, adopting the cutoff for exclusion 
used by Tee et al. 22.
To design the intervention with 40 children in 
each treatment arm, with the aim of detecting a 
minimum difference of 0.5g/dL with a standard 
deviation of 0.7 and significance of 0.05, the test 
power was 0.89. This sample size is sufficient to 
detect differences of the same magnitude be-
tween the groups. The SAMPSI procedure from 
Stata 7.0 (Stata Corp., College Station, USA) was 
used for calculation.
A safety margin of 24% was added to the ini-
tially predicted sample of 160 children to cover 
potential losses during the study. Of the 219 
selected children, eight left the daycare center, 
four failed to appear for blood samples, and the 
parents of eight canceled the original informed 
consent. Thus, 199 children participated in the 
first blood draw. Of these, three did not perform 
the complete blood count, so the assessment of 
anemia prevalence used a sample of 196 children 
that participated in the subdivision of groups for 
the clinical trial (Figure 1). Since four children 
presented hemoglobin ≥ 7 and < 8.0g/dL, they 
were submitted to special treatment prescribed 
by the pediatrician and were therefore excluded. 
Thus, from the initial sample to the randomiza-
tion for the clinical trial, a sample of 192 children 
was established, but eight of them left the daycare 
centers before beginning medication. Therefore, 
184 children actually began treatment with fer-
rous sulfate, and 161 of them (87.5%) concluded 
the treatment (Figure 1). Thus, there was a loss of 
12.5% among the children that began treatment, 
and a total sample loss of 19.1% (161/199) among 
those that appeared for the first blood sample 
until the end of the experiment.
Study design
The current study was part of a larger project called 
Nutritional Anemia: Prevention and Treatment in 
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Early Childhood, which aimed to assess the cau-
sality of anemia and diet and to compare differ-
ent micronutrient supplements in the prevention 
and treatment of anemia in early childhood. The 
study done in Goiânia from April 2005 to March 
2006 was therapeutic, according to the Medical 
Research Council (MRC), since it involved both 
treatment and prevention of diseases 23.
This was a controlled, randomized, prospec-
tive, double-blind clinical trial with 192 children 
from 6 to 24 months of age. The design was lon-
gitudinal, and the research unit was children in 
this age bracket on the date the first blood sample 
was drawn. 
After informing the children’s parents/guard-
ians and obtaining written informed consent in 
duplicate, the first interview was held for sample 
selection and screening by the pediatrician to de-
termine whether the child was eligible to partici-
pate in the study.
The study collected socioeconomic and cul-
tural data and information on the parents; re-
Figure 1  
Clinical trial fl owchart.
CBC: complete blood count.
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alizes food and anthropometric surveys, blood 
counts and blood chemistry, stool tests, and fecal 
occult blood. Clinical examination of the partici-
pating children, using a previously tested form 
with modifications 14 and clinical charts. The in-
terviewers were students, interns, and scientific 
initiation or extension scholarship students from 
the undergraduate course in nutrition, as well 
as a nutritionist and faculty members from the 
School of Nutrition, Federal University in Goiás 
(UFG), all previously trained.
Parents were informed that the blood tests 
posed no risk of contamination or infection, and 
that they could cancel their consent at any time, 
without harm the care provided to their chil-
dren.
Intervention
For the intervention, the daycare centers were di-
vided into four groups. Groups A and C received 
ferrous sulfate at different concentrations plus 
folic acid placebo for the prevention and treat-
ment of anemia, and Groups B and D received 
ferrous sulfate plus folic acid. 
• Group A: daily treatment with 4.2mg/kg/day 
of ferrous sulfate + folic acid placebo.
• Group B: daily treatment with 4.2mg/kg/day 
of ferrous sulfate + folic acid (50µg/day).
• Group C: daily prophylaxis with 1.4mg/kg/day 
of ferrous sulfate + folic acid placebo.
• Group D: daily prophylaxis with 1.4mg/kg/day 
of ferrous sulfate + folic acid (50µg/day).
Ferrous sulfate drops were used with 25mg 
of elemental iron per mL. The dose administered 
to each child was calculated and prescribed by 
the pediatrician responsible for the children’s fol-
low-up, prevention, and treatment, based on the 
child’s body weight as measured on the day of the 
first blood sample. Anemic children were treat-
ed with 4.2mg/kg/day of ferrous sulfate, with or 
without folic acid, administered five days a week 
(Monday to Friday), the equivalent of a mean dai-
ly treatment dose of 3mg/kg/day 4. Non-anemic 
children (Hb ≥ 11g/dL) received 1.4mg/kg/day of 
ferrous sulfate five days a week, corresponding to 
a daily dose of 1mg/kg/day. This is the dose rec-
ommended by the Brazilian Society of Pediatrics 
since 1995, beginning with the introduction of 
food supplementation at 24 months of age 24, and 
by the American Academy of Pediatrics for term 
infants with birth weight > 2,500g 25. 
Folic acid supplementation of 50µg/day was 
based on Stoltzfus & Dreyfuss 20.
The pediatrician provided one copy of the 
test results to the mothers. The number of drops 
to be administered was written on a medical pre-
scription that was kept in the daycare center, and 
these amounts were also recorded on the medi-
cation sheet. 
The teachers, school staff, and nutrition in-
terns were trained to administer the medication 
and record the data on the forms. The interns also 
acted as supervisors, and every two to three days, 
besides administering the medication (ferrous 
sulfate and then folic acid drops), they checked 
the forms to see whether the teachers or school 
staff had properly administered and recorded the 
medication on the other days of the week. On the 
days without supervision, the control was also 
done by means of telephone calls. 
The children in each group of daycare centers 
received a median of 67 doses of medication. At 
the end of treatment, they had new blood counts 
and blood chemistry tests. Children that pre-
sented anemia and/or iron deficiency at the sec-
ond examination received ferrous sulfate for two 
more months, furnished free of cost. Parents were 
instructed to bring their children to the nearest 
health clinic for a follow-up examination.
Blinding and use of placebo
Blinding was applied to the folic acid. In this 
study the mothers (who were informed ahead of 
time) and the other participants did not know 
whether folic acid or folic acid placebo was be-
ing administered. The variable with the type of 
medication administered was only included after 
duplicate keying-in of the data and performing 
VALIDATE in Epi Info 6.04d (Centers for Disease 
Control and Prevention, Atlanta, USA). 
The placebo and folic acid were manufac-
tured by a pharmaceutical company according 
to the required standards, using identical bottles 
and packaging, distinguished only by the batch 
number, with no potential conflict of interests. A 
control card was used to deliver the medicines to 
the daycare centers, to avoid possible switching 
of batches.
Blood counts and blood biochemistry
At baseline and at the end of treatment, aliquots 
of 8 to 10mL of fasting venous blood were drawn 
with disposable syringes and needles, placed in 
three separate tubes for: (1) a complete blood 
count (CBC); (2) folic acid and vitamin B12 anal-
ysis, with the tube wrapped in aluminum foil; 
and (3) ferritin and C-reactive protein, the latter 
capable of increasing ferritin in the presence of 
infection 4,26. 
CBC was performed with electronic counting 
in Cell-Dyn 3200 SL (Abbott Diagnostics, Mount 
View, USA), obtaining hemoglobin levels. Chil-
dren with hemoglobin < 11g/dL were considered 
SUPPLEMENTATION FOR THE PREVENTION AND TREATMENT OF ANEMIA S263
Cad. Saúde Pública, Rio de Janeiro, 24 Sup 2:S259-S271, 2008
anemic 4. Severity of anemia was classified as: 
severe when Hb < 7.0g/dL; moderate with Hb ≥ 
7.0 and < 9.0g/dL; and mild with Hb ≥ 9.0 and < 
11g/dL 27.
Serum ferritin was assessed by chemolumi-
nescence in the AxSym system by Abbott Labora-
tories of Brazil Ltd., using the specific kit. 
Serum C-reactive protein (CRP) was mea-
sured by turbidimetry in Konelab 60i (Wiener, 
Finland) at the Clinical Laboratory of the Univer-
sity Hospital of the Federal University in Goiás. 
Children with CRP < 0.50 were considered in-
flammation-free. 
Serum folate and vitamin B12 were measured 
by chemoluminescence with the Bayer Advia 
Centaur System (Bayer Diagnostics, Tarrytown, 
USA) at the Hermes Pardini Institute in Belo 
Horizonte. The cutoff points for detecting folic 
acid deficiency were < 3.0ng/mL for high risk of 
deficiency, 3-5ng/mL for moderate risk, and > 
5ng/mL for low risk 28; vitamin B12 levels from 
120 to 200pg/mL were considered borderline and 
< 120pg/mL as B12 deficiency 29.
Monthly weight gain
The children were weighted undressed at the 
time of the first blood sample on an electronic 
platform scale by Kratos (Kratos Cas, Taboão da 
Serra, Brazil) with a capacity of 150kg, accurate 
to 50g, with tare function. Weight was measured 
to obtain mean monthly weight gain, defined as 
the difference between current weight and birth 
weight, divided by the decimal age, expressed in 
months and days.
Statistical analysis
The coded data were entered in duplicate, per-
forming VALIDATE in Epi Info 6.04d. Statistical 
analyses used Statistical Package for the Social 
Sciences version 10.0 (SPSS Inc., Chicago, USA). 
Statistical analyses used the following tests: 
Kolmogorov-Smirnov to assess goodness-of-fit 
with normal distribution, chi-squared, Student’s 
t, Fisher’s exact, paired samples t, and Mann-
Whitney tests, with a significance level of 0.05 
or 5%.
Treatment effect was estimated as the ab-
solute risk reduction, relative risk, and relative 
risk reduction. Absolute risk reduction is the dif-
ference in risk between the control group (CR) 
and treatment group (TR). Relative risk (RR) is 
the ratio between risk in the treated group and 
control group. Relative risk reduction expresses 
the percentage reduction in events in the treat-
ment group (TR) as compared to controls (CR), 
expressed as [(CR-TR)/CR] x 100%. Meanwhile, 
the number needed to treat is the absolute risk 
reduction number, that is, it demonstrates the 
number of patients that need to be treated to 
avoid one case of anemia 30.
Study protocol no. 098/04 was approved by 
the Institutional Review Board at the University 
Hospital of the Federal University in Goiás (UFG) 
on December 10, 2004. 
Results
Anemia prevalence
The 196 children from the 25 municipal daycare 
centers were 6 to 24 months of age when the 
baseline blood sample was drawn and showed an 
anemia prevalence of 56.1% (95%CI: 48.9-63.1). 
No children had severe anemia, while 17 (8.7%; 
95%CI: 5.3-13.7) showed moderate anemia and 
93 (47.4%; 95%CI: 40.3-54.7) had mild anemia. 
Mean hemoglobin in the anemic children was 
9.9 ± 0.8dL.
Clinical trial
Figure 1 shows the flowchart of children that par-
ticipated in the clinical trial. Children with hemo-
globin ≥ 7.0 and < 8.0g/dL (n = 4), i.e., 2% of the 
children, were excluded from the clinical trial, 
since they began treatment with higher doses of 
ferrous sulfate, administered twice a day. The at-
tending pediatrician prescribed the medication 
for all the children participating in the study and 
those excluded from it. Thus, of 196 children with 
a baseline complete blood count, 192 participat-
ed in the clinical trial, and of these 106 were ane-
mic (55.2%) and 86 were non-anemic (44.8%).
Characteristics of participants in the 
clinical trial
Table 1 shows the characteristics of the 192 par-
ticipants in the four intervention groups and the 
families’ socioeconomic conditions. Among the 
participants, 97.4% were from Goiânia and five 
(2.6%) from Aparecida de Goiânia. 
The study compared the characteristics of 
anemic and non-anemic children that received 
ferrous sulfate plus folic acid with those that re-
ceived ferrous sulfate plus folic acid placebo. No 
significant differences were observed in gender, 
decimal age in months, birth weight, per capita 
income (in times the minimum wage), base-
line hemoglobin, baseline ferritin after exclud-
ing children with infection (CRP ≥ 0.5), housing 
conditions, and maternal schooling. The groups 
were thus homogeneous (Table 1).
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There was a statistically significant difference 
in relation to hemoglobin level and decimal age 
(months) at the time of the first blood count, 
when comparing anemic and non-anemic chil-
dren (data not shown). 
When evaluating whether the children that 
concluded treatment differed from those that 
dropped out, no significant difference was ob-
served in serum hemoglobin, folic acid, vita-
min B12, or ferritin in relation to gender, per 
capita family income, maternal schooling, mean 
monthly weight gain, and proportion of anemic 
subjects. Only decimal age was lower among 
treatment dropouts (Table 2).
Effects of the intervention 
Table 3 shows the effects of treatment for ane-
mia in the treatment and control groups with and 
without folic acid.
Among the anemic children that completed 
treatment with ferrous sulfate plus folic acid, 
final anemia prevalence was 14%. However, 
among the anemic children that received fer-
rous sulfate plus folic acid placebo, final anemia 
prevalence was 34.9%. Folic acid was a protec-
tive factor for the reduction of anemia preva-
lence (p = 0.02), as shown by comparison to 
anemic children that received folic acid placebo 
(Table 3).
The incidence of anemia among children that 
received prophylactic iron plus folic acid was 
lower than those receiving iron plus folic acid 
placebo, but the difference was not statistically 
significant (Table 3).
Final prevalence of anemia in anemic and 
non-anemic children treated with ferrous sulfate 
plus folic acid was 10.1% (8/79), as compared to 
23.2% (19/82) among those that received ferrous 
sulfate plus placebo (Table 3).
Table 1  
Baseline characteristics of subjects in each group before supplementation with iron plus folic acid versus iron plus folic acid placebo *.
 Variables Anemic P Non-anemic P
   Folic acid Placebo  Folic acid Placebo 
 Male gender (%) 57.7 (30/52) 55.6 (30/54) 0.85 ** 56.8 (25/44) 38.1 (16/42) 0.09 **
 Age (months) 14.8 ± 3.7 *** 14.3 ± 4.5 0.55 # 16.3 ± 3.9 16.9 ± 3.1 0.42 #
 Birth weight (g) 3.278 ± 389 3.387 ± 444 0.18 # 3.316 ± 382 3.420 ±367 0.20 #
 Baseline hemoglobin (g/dL) 10.0 ± 0.8 9.9 ± 0.7 0.30 # 11.7 ± 0.6 11.8 ± 0.6 0.52 #
 Baseline ferritin (µg/L) ## 3.8 (1.1-6.4) *** 6.3 (2.8-11.9) 0.13 ### 9.5 (5.7-14.5) 6.2(4.3-14.8) 0.37 ###
 Monthly per capita family  0.38 (0.25-0.68) 0.33 (0.22-0.52) 0.26 ### 0.59 ± 0.4 *** 0.70 ± 0.4 0.20 #
 income (minimum wage) * 
 Maternal schooling (years)      
  0-4 13 6 0.10 ** 8 4 0.34 **
  5-8 20 30  18 15 
  ≥ 9 19 18  18 23 
 Home *      
  Own or loaned 19 27 0.19 ** 19 22 0.39 **
  Rented or financed home  32 27  25 20 
 Water       
  Treated 46 49 0.95 ** 42 37 0.26 §
  Cistern 6 5  2 5 
 Sewage disposal      
  Sewerage 34 31 0.40 ** 24 26 0.49 **
  Cesspool or open ditch 18 23  20 16 
* Excluding children with hemoglobin ≥ 7 and < 8g/dL; one child lived in a squatting settlement. All the children received a therapeutic or prophylactic dose of 
ferrous sulfate plus folic acid or placebo;
**  χ2 test;
*** Mean ± standard deviation or median (P25 - P75);
# Student’s t test for independent samples;
## Excluding children with infection (PCR ≥ 0.5) from the ferritin analysis;
### Mann-Whitney test;
§ Fisher’s exact test.
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The absolute risk reduction was 0.21. Thus, 
the group treated with active folic acid showed 
21% less anemia than the group that received fo-
lic acid placebo.
The group treated with folic acid showed a 
relative risk of anemia of 0.40 (95%CI: 0.17-0.93) 
compared to the control group, showing that the 
intervention was highly beneficial. The risk of 
remaining anemic in the placebo group was 2.5 
times that of the group that received folic acid. 
The odds ratio was 0.3, i.e., similar to the value 
obtained for relative risk.
Relative risk reduction was 60%, meaning 
that treatment with ferrous sulfate plus folic acid 
allowed a 60% reduction in anemia compared to 
the group treated with ferrous sulfate plus folic 
acid placebo.
The number needed to treat (NNT) with fer-
rous sulfate and folic acid to avoid anemia was 
five patients treated to avoid one case of anemia.
Pre and post-treatment hemoglobin levels 
showed a significant increase in anemic individ-
uals, both for those that received folic acid and 
those receiving placebo. Among non-anemic in-
dividuals, the increase only occurred in the group 
that received folic acid (p = 0.003). However, there 
was no statistically significant difference when 
comparing hemoglobin levels between the active 
folic acid and placebo groups (Table 4). 
Table 2  
Comparison of subjects that concluded treatment and dropouts *.
 Variables Concluded Dropped out of p
   n Treatment n Treatment 
 Baseline hemoglobin (g/dL) 161 10.8 ± 1.1 31 10.7 ± 1.1 0.81 **
 Baseline folic acid (ng/mL) 157 13.0 ± 5.4 31 12.7 ± 5.0 0.75 **
 Birth weight (g) 160 3.369 ± 387 30 3.398 ± 471 < 0.46 **
 Decimal age (months) *** 161 15.9 ± 4.0 31 13.4 ± 3.5 0.002 **
 Male gender (%) 161 54 (87/161) 31 45.2 (14/31) 0.36 #
 Per capita income (no. times the minimum wage) 161 0.41 (0.25-0.70) 31 0.50 (0.38-0.69) 0.12 ##
 Maternal schooling (years) 161  31  0.45 #
  0-4  24  7 
  5-8  69  14 
  ≥ 9  68  10 
 Mean monthly weight gain (g) 159 434 (381-530) 29 456 (426-563) 0.11 ##
 Baseline ferritin (µg/L) 148 8.1 (4.3-18.5) 31 10.2 (3.3-18.7) 0.85 ##
 Baseline vitamin B12 (pg/mL) 157 565 (427-719) 31 502 (371-732) 0.29 ##
 Anemic (%) 161 53.4 (n = 86) 31 64.5 (n = 20) 0.26 #
* Excluding children with hemoglobin ≥ 7 and < 8g/dL. Mean ± standard deviation or median (P25 – P75);
** Student’s t test;
*** Decimal age, expressed as age in months and days;
# χ2  test;
## Mann-Whitney test.
Table 3  
Prevalence of anemia in children with baseline anemia and incidence in non-anemic children 
after therapeutic or prophylactic dose.
 Group Final anemia Total
   Yes No n %
 Baseline anemia *.**    
  Treated with com iron + folic acid *** 6 37 43 14.0
  Treated with iron + folic acid placebo # 15 28 43 34.9
 Non-anemic ##    
  Prophylaxis with iron + folic acid 2 34 36 5.6
  Prophylaxis with iron + folic acid placebo 4 35 39 10.3
* χ2 calc = 5.10; p = 0.02;
** Absolute risk reduction: 0.35 - 0.14 = 0.21; Relative risk reduction: [(0.21/0.35)] X 100.0% 
= 60.0%; Number needed to treat: 1/0.21 = 5;
*** Risk in treated group: 6/43 = 0.14;
# Risk in control group: 15/43 = 0.35;
## Fisher’s exact test,  p = 0.38.
Number of doses received
When evaluating the number of doses or days of 
medication, we observed that the 25th percen-
tile, median, and 75th percentile in the number of 
doses received were 66, 67, and 70, respectively in 
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both the anemic (n = 86) and non-anemic group 
(n = 75). The Mann-Whitney test showed that 
the two groups did not differ as to the number of 
doses received (p = 0.71).
Comparing the anemic and non-anemic 
groups, there was also no difference in the num-
ber of doses received in the folic acid group as 
compared to the placebo group. 
The number of doses or scheduled days of 
treatment was 67 days, so no children that par-
ticipated in the second post-intervention blood 
sample showed low adherence (i.e., no children 
received fewer than 75% of the scheduled doses). 
Serum folic acid in children in the clinical trial
Among the children with baseline anemia, serum 
folic acid levels did not differ between the groups. 
However, after the intervention the active folic 
acid group showed significantly higher folic acid 
levels than the placebo group (Table 5). Folic acid 
level increased significantly after supplementa-
tion with ferrous sulfate plus folic acid, but not 
with ferrous sulfate and placebo (Table 5).
Among children without baseline anemia, 
serum folic acid did not differ from the first to 
the second blood sample. Although there was an 
upward trend in the folic acid group, it was not 
statistically significant (p = 0.055, Table 5). 
Discussion
The current study was part of a larger research 
project on the assessment of nutritional ane-
mia in early childhood, conducted at munici-
pal daycare centers in Goiânia. The principal 
focus was supplementation with two micronu-
trients, iron and folic acid, to prevent and treat 
anemia. 
The municipal daycare centers contribute 
to the child’s development and allow the moth-
er to participate in the labor market, which in 
turn leads to greater availability of food in the 
home 31. However, if the center is located far 
from the mother’s workplace, it does not allow 
exclusive breastfeeding up to six months of age, 
considering that the official maternity leave in 
Brazil is only four months.
According to one study, children enrolled in 
a daycare center showed improved nutrient in-
take 32, while another study showed inadequate 
food consumption among children attending a 
daycare center 31. 
The prevalence of anemia in this study 
(56.1%) among children 6 to 24 months of age 
in the 25 municipal daycare centers in Goiânia 
is similar that in other studies performed in the 
same city. Hadler et al. 33 observed a 60.9% ane-
mia prevalence in 110 infants 6 to 12 months 
of age, while in a study in daycare centers with 
children 1 to 48 months of age the prevalence 
was 51% 34. Other Brazilian studies have shown 
even higher prevalence than in the current 
study. In municipal daycare centers in the city 
of São Paulo, prevalence of anemia was 65.3% 
among children 6 to 12 months of age and 69% 
from 12 to 24 months 14. In Cuiabá, the preva-
lence was 82% in children 6 to 24 months of 
age 35. Analyzed jointly, these data confirm that 
Table 4  
Mean hemoglobin concentrations (g/dL) in anemic and non-anemic children before and after treatment with ferrous sulfate 
plus folic acid or folic acid placebo *.
 Groups/Variables n Baseline Hb Final Hb p Hb increase
    Mean ± SD Mean ± SD  Mean ± SD
 Treatment of anemic subjects     
  Fe + folic acid  43 9.96 ± 0.77 11.5 ± 0.8 < 0.001 ** 1.56 ± 0.91
  Fe + folic acid placebo 43 9.93 ± 0.7 11.3 ± 1.0 < 0.001 ** 1.32 ± 1.2
  Folic acid X placebo   p = 0.87 *** p = 0.19 ***  
 Prophylaxis in non-anemic     
  Fe + folic acid  36 11.7 ± 0.58 12.1 ± 0.8 0.003 ** 0.41 ± 0.78
  Fe + folic acid placebo 39 11.8 ± 0.58 12.0 ± 0.9 0.07 ** 0.25 ± 0.85
  Folic acid X placebo   p = 0.68 *** p = 0.59 ***  
SD: standard deviation.
* Excluding children with hemoglobin ≥ 7 and < 8g/dL;
** Paired samples t test;
*** Student’s t test applied to the children that participated in both blood samples.
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children less than 24 months of age constitute 
one of the main risk groups for anemia 10,36,37.
In the municipal daycare centers in this study, 
among anemic children less than 18 months of 
age, 17.9% (15/84) showed Hb < 9.0g/dL, while 
in the city of São Paulo similar hemoglobin levels 
were found in one-third of anemic children in 
this age bracket 15.
Food fortification, supplementation, and nu-
tritional education programs have been recom-
mended to fight anemia4. In Brazil, Ruling RDC 
344 of December 13, 2002 38 requires fortification 
of wheat flour and corn meal and corn flakes with 
4.2mg of bioavailable iron and 150µg of folic acid 
per 100g of food product, as one of the measures 
to fight anemia and reduce the risk of neural tube 
defects and myelomeningocele.
Supplementation with ferrous sulfate and 
folic acid to treat anemia proved more effective 
than ferrous sulfate with placebo and was a pro-
tective factor against anemia, since the reduction 
in anemia prevalence was significantly greater. 
Although the children did not present folic ac-
id deficiency at baseline, administration of this 
micronutrient allowed a significant increase in 
serum folic acid and a greater and quicker re-
duction in anemia prevalence. This proves that 
folic acid can be combined with ferrous sulfate 
supplementation to treat anemia.
The Brazilian Ministry of Health created the 
National Iron Supplementation Program to pre-
vent anemia in children from 6 to 18 months of 
age, using 25mg of elemental iron/week 40. A 
scientific report by the Department of Nutrition 
of the Brazilian Pediatric Society in February 
2007 40 contends that the above supplementa-
tion has still not been properly proven, espe-
cially in Brazil, and recommends, for prophy-
laxis of anemia, that when infants (born at term 
with adequate-for-gestational age birth weight) 
begin receiving complementary food (besides 
breastfeeding), they should receive 1mg of el-
emental iron/kg body weight/day unless they 
consume a minimum of 500mL/day of iron-
Table 5  
Serum folic acid (ng/mL) in anemic and non-anemic children that received ferrous sulfate plus folic acid or placebo in the pre 
and post-intervention periods *.
 Groups and time of  Folic acid group Placebo group p
 blood sample n Serum folic acid n Serum folic acid 
    Mean ± SD  Mean ± SD 
 Anemic     
   Pre 50 11.0 ± 4.7 52 12.8 ± 4.8 0.065 **
   Post 43 14.6 ± 4.8 43 12.4 ± 4.3 0.027 **
  Folic acid group     
   Pre 41 10.7 ± 4.6   < 0.001 ***
   Post 41 14.8 ± 4.8   
  Placebo group     
   Pre   41 13.0 ± 5.1 0.507 ***
   Post   41 12.4 ± 4.2 
 Non-anemic     
   Pre 44 13.5 ± 5.7 42 15.0 ± 5.4 0.197 **
   Post 36 15.6 ± 5.2 39 15.1 ± 5.1 0.688 **
  Folic acid group     
   Pre 36 13.3 ± 5.5   0.055 ***
   Post 36 15.6 ± 5.2   
  Placebo group     
   Pre   39 15.3 ± 5.5 0.861 ***
   Post   39 15.1 ± 5.1 
SD: standard deviation.
* Excluding children with hemoglobin ≥ 7 and < 8g/dL and those without hemoglobin values from the second blood 
sample;
** Student’s t test for independent samples;
*** Paired samples t test.
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enriched baby formula 40. The existence of two 
different recommendations hinders the imple-
mentation of a supplementation program.
Silva 16 compared different doses of ferrous 
sulfate for prevention of anemia in children 6 to 
12 months of age and showed that the daily dose 
of 1mg/kg/day recommended by the Brazilian 
Pediatric Society 40, which is the dose used in 
the current study, had better results than 2mg/
kg/day, or the weekly dose recommended by the 
Ministry of Health.
Definition of the recommended dose is also 
based on the child’s iron nutritional status 4. Ane-
mic children receive a therapeutic dose, while 
non-anemic children receive prophylactic doses, 
like those administered in this and other studies 
in Brazil 4,16,35. However, some studies have used 
the same amount of iron for both prevention and 
treatment of anemia 15,41,42.
The results of the current intervention dem-
onstrate that the administration of 4.2mg of fer-
rous sulfate/kg/day significantly increased the 
hemoglobin level in anemic children, both in 
groups receiving folic acid and those receiving fo-
lic acid placebo. The reduction in the prevalence 
of anemia was higher in those that also received 
folic acid, and although the increase in hemo-
globin (1.56 ± 0.91g/dL) was higher than in those 
that received placebo (1.32 ± 1.2g/dL), the differ-
ence between the two groups was not statistically 
significant (p = 0.19). There are controversies as 
to the effect of iron and micronutrient supple-
mentation on child morbidity 43,44, including the 
non-recommendation of prophylaxis in areas 
with a high prevalence of malaria 44. 
Even some non-anemic children that re-
ceived a prophylactic dose of ferrous sulfate pre-
sented anemia, in both the active folic acid and 
placebo groups. Other studies have also shown 
some anemia incidence in children receiving a 
prophylactic dose, using different types of iron in 
the medication 16,45.
In the non-anemic children, the final ane-
mia incidence did not differ between the groups, 
although there was an increase in hemoglobin 
among those receiving ferrous sulfate plus folic 
acid (p = 0.003), but not in those receiving place-
bo. Still, final hemoglobin did not differ between 
the two groups. 
Conclusions and recommendations
Anemia prevalence was high in under-two chil-
dren attending municipal daycare centers in 
Goiânia, even with the use of iron and folic acid 
supplemented flours. 
A supplementation program with ferrous 
sulfate and folic acid, as developed in this study, 
proved effective in the reduction of anemia prev-
alence in children and improved the hemoglobin 
levels in non-anemic children. Such a program 
is easy to implement and does not require that 
the mother administer the medication at home. 
The children require nutritional follow-up and 
monitoring of anemia, and this type of program 
can be developed at municipal daycare centers 
or preschools. 
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Resumo
Avaliar a prevalência de anemia e a resposta terapêu-
tica e profilática do sulfato ferroso e ácido fólico. Re-
alizou-se um ensaio clínico controlado randomizado, 
duplo-cego, com 196 crianças de 6 a 24 meses, dos Cen-
tros Municipais de Educação Infantil de Goiânia, Goi-
ás, Brasil. As crianças foram alocadas em dois grupos 
de tratamento que receberam dose diária (5x/sema-
na) com 4,2mg/kg/dia de sulfato ferroso + ácido fólico 
(50µg) ou 4,2mg/kg/dia de sulfato ferroso + placebo de 
ácido fólico. Um dos grupos de prevenção recebeu 1,4 
mg/kg/dia de sulfato ferroso + ácido fólico (50µg/dia) 
e o outro 1,4mg/kg/dia de sulfato ferroso + placebo 
de ácido fólico. A suplementação durou cerca de três 
meses. A prevalência de anemia inicial foi de 56,1% 
(IC95%: 48,9-63,1). Após o tratamento, a prevalência 
de anemia no grupo ácido fólico (14%) foi menor que 
no grupo placebo (34,9%; p = 0,02). Após profilaxia dos 
não anêmicos, a incidência de anemia não diferiu en-
tre os grupos, porém, houve incremento da hemoglobi-
na no grupo ácido fólico (p = 0,003). O ferro associado 
com ácido fólico foi eficaz no tratamento da anemia e 
na melhoria da hemoglobina nos não anêmicos.
Epidemiologia Nutricional; Anemia; Sulfato Ferroso; 
Ácido Fólico; Creches
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